RORgammat modulators / Karo Pharma - LARVOL DELTA

Karo Bio announces extension of existing collaboration with Pfizer to discover and develop drugs for autoimmune diseases (Businesswire) - Karo Bio "announced today the extension of its existing research collaboration with Pfizer Inc. on RORgamma modulators to the end of 2014....The nuclear hormone receptor RORgamma is a novel attractive target for the treatment of autoimmune diseases like rheumatoid arthritis, multiple sclerosis and psoriasis."

Licensing / partnership • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis

Interim report January-June 2014 (Karo Bio Press Release) - "The collaboration with Pfizer in the RORgamma project is in an exciting phase with a number of important tests. Continued positive development of the project may also trigger further milestone payments from Pfizer to Karo Bio."

Anticipated commercial • Pipeline update • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis